Therefore, after the positive results obtained in vitro and in vivo on inhibition of growth of different KRAS G12C mutated cells, new drugs are currently under evaluation on patients in different clinical trials and should soon be administered in daily practice to advanced or metastatic NS-NSCLC patients showing a KRAS G12C mutation [30,129,130]. Here, KRAS is linked to non-small cell lung carcinoma.